Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2020 - 2026)
Summit Therapeutics (SMMT) reported Depreciation & Amortization (CF) of $44000.0 for Q1 2026, up 76.0% on a YoY basis from $25000.0 in Q1 2025, and up 4.76% quarter-over-quarter from $42000.0 in Q4 2025.
Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Summit Therapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $44000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 76.0% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $165000.0 (up 89.66% YoY), and the FY2025 full-year result was $146000.0, up 64.04% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $44000.0, up from $42000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $99000.0 in Q2 2022, with the low at $20000.0 in Q2 2024.
- Historically, Depreciation & Amortization (CF) has averaged $48588.2 across 5 years, with a median of $42000.0 in 2025.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 70.0% — and 2025, when it soared 110.0%.
- Summit Therapeutics' Depreciation & Amortization (CF) stood at $88000.0 in 2022, then slumped by 65.91% to $30000.0 in 2023, then fell by 26.67% to $22000.0 in 2024, then jumped by 90.91% to $42000.0 in 2025, then rose by 4.76% to $44000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $44000.0 (Q1 2026), $42000.0 (Q4 2025), and $42000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |